Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736416 | 0.91 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL29613341 | 0.91 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL1736042 | 0.91 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL29794337 | 0.89 | CYP2C19 (0.56) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL1736266 | 0.88 | NPY1R (0.55) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL29398996 | 0.85 | CYP1A2 (0.54) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL1738251 | 0.84 | CYP2C19 (0.51) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL27898034 | 0.84 | CYP2C19 (0.65) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL1735525 | 0.84 | CYP2C19 (0.65) | NOS2CYP2C19CYP1A2GLATSHR | |
| SCHEMBL1736568 | 0.83 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2GLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | claimed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| CN-114341158-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-118955620-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118930608-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114341158-B | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-114341158-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | NOS2 3661/4885CYP2C19 4490/4885CYP1A2 3918/4885 |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | NOS2 3661/4885CYP2C19 4490/4885CYP1A2 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.